What is being evaluated
in the DIAMOND trials?

OCS-01 is an investigational eye drop developed with the proprietary OPTIREACH® technology that enables the active ingredient, dexamethasone, to reach the back of the eye.1 This allows for a potential treatment for DME that is non-invasive and does not require an injection in the eye or surgery.2

The goal of the DIAMOND trials is to determine if OCS-01 is safe and effective in treating DME in adults.2

OCS-01 is an investigational eye drop and has not received regulatory approval for commercial use in any country.

Learn more about the DIAMOND trials and associated requirements to see if you could participate.
Get Details
Both DIAMOND Phase 3 trials of OCS-01 have been reviewed by Advarra Institutional Review Board Services in the U.S. and determined to be safe for participants.

OCS-01 is an investigational product and has not been approved by the FDA. Safety and efficacy of OCS-01 for diabetic macular edema have not been established.

References

1. Hutton D. First Investigational Eye Drop for Front and Back of the Eye Met Both Primary Endpoints in Phase 3 OPTIMIZE Trial. Accessed August 5, 2024. https://www.ophthalmologytimes.com/view/first-investigational-eye-drop-for-front-and-back-of-the-eye-met-both-primary-endpoints-in-phase-3-optimize-trial. 2. Study of the Efficacy and Safety of OCS-01 Eye Drops in Subjects With Diabetic Macular Edema (DIAMOND-2). NCT06172257. Accessed August 2, 2024. https://clinicaltrials.gov/study/NCT06172257.